Skip to content

Further Research Priorities

These are remaining evidence and synthesis gaps after the September 2026 reviews. The current direction is a broad content review across products, implementation, standards and national context. Use What Next: Suggestions and Decisions for the disposition, scope and completion criteria of proposed follow-ups. Detailed supplier-response targets remain in the Evidence Validation Queue; they are not the default research agenda.

  1. Comparable product evidence. Comparative Analysis now distinguishes product roles and documents HAPI FHIR and Azure Health Data Services as FHIR comparators. Equivalent integration-engine and EHR workflows, operating effort, cost and independent outcomes remain unsourced. Compare like-for-like scope before drawing conclusions about suitability.
  2. Current NHS deployment coverage. UK NHS Digital Connectivity and Interoperability Evidence combines awards, support contracts, phased deployments and live-use reports. The UK Clinical Platform Estate now supplies a substantial site/function/status/source baseline. Reconcile remaining coverage and deeper implementation/outcome gaps against it before requesting another inventory (WN-008). Prioritise public customer records that change those distinctions.
  3. An end-to-end clinical-data example. The standards overview now explains the layers, but the synthesis lacks a complete example connecting a clinical entry, terminology, message, receiving system and displayed record. Use existing TrakCare, Health Connect and HealthShare pages to show the sequence, labelling proposed steps separately from documented interfaces.
  4. Software and service responsibilities. The product portfolio distinguishes software, managed services and optional modules. Public service-specific documentation is still needed for a consistent comparison of hosting, release control, monitoring, recovery and support. Keep software availability separate from tenant rollout and customer upgrades.
  5. Selected four-nation workflow gaps. The UK Core Services Matrix and country pages now provide the broad functional comparison, including urgent care. Remaining work is narrower: a named GP operation may need supplier-interface evidence (WN-001); the existing registration/identity findings could be made easier to understand in one worked model (WN-002). Do not repeat the broad mapping exercise or treat every unverified cell as an active research task.
  6. Recording duties in everyday use. UK Healthcare Recording contains the legal and professional sources. The remaining synthesis gap is a plain example of creating, correcting, sharing and retaining a record that preserves the distinctions between professional duties, confidentiality, data protection and local clinical-safety controls.

IntelliCare/EMC pilot outcomes, West Midlands supplier/FOI targets, unresolved ITK/PRSB scope, current IRIS GP Connect status and the CORTISONE implementation-proof pack remain recorded in their existing pages and queue entries. The user redirected work toward breadth on 9 September 2026. Reopen a narrow trail for a specific question, new material evidence or an active assurance decision; do not turn the freshest unanswered question into another default follow-up pass.

No additional page, request pack or evidence-domain layer is needed for these priorities. Complete the missing synthesis in the existing pages first.

Content, Narrative and Presentation Work

The 16 September 2026 review identified synthesis and implementation gaps in reader progression, overview/detail balance, visible evidence access and history/source preservation. Six scoped passes, their To Do status and completion criteria are held in the Future Content and Narrative Work queue. Complete that work within existing pages; recording the review does not implement the proposed changes.